硫代乙酸-(3-氯-苯胺) | 29452-11-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 硫代乙酸-(3-氯-苯胺)
• 英文名称: N-(3-chlorophenyl)ethanethioamide
• 英文别名: thioacetic acid-(3-chloro-anilide)；Thioessigsaeure-(3-chlor-anilid)；N-(3-chlorophenyl)thioacetamide
• CAS: 29452-11-7
• 化学式: C₈H₈ClNS
• 分子量: 185.677
• InChiKey: BRYQQGRGBHZNOA-UHFFFAOYSA-N

物化性质

• 沸点：
  256.4±42.0 °C(Predicted)
• 密度：
  1.304±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  44.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  硫代乙酸-(3-氯-苯胺) 在 sodium hydroxide 、 potassium hexacyanoferrate(III) 作用下， 生成 5-氯-2-甲基苯并噻唑
  参考文献：
  名称：

  Mizuno; Adachi, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1956, vol. 76, p. 333

  摘要：

  DOI：
• 作为产物：
  描述：

  3-氯乙酰苯胺 在 劳森试剂 作用下， 以 甲苯 为溶剂， 反应 2.0h， 以71%的产率得到硫代乙酸-(3-氯-苯胺)
  参考文献：
  名称：

  [EN] SMALL MOLECULE INHIBITORS OF GALECTIN-3
  [FR] INHIBITEURS À PETITES MOLÉCULES DE GALECTINE-3

  摘要：

  公开号：

  WO2019067702A9

文献信息

• 5-methylthio-3-hydroxybenzo [b]thiophene-2-carboxamide derivatives as
  申请人：Merck & Co., Inc.

  公开号：US04800211A1

  公开（公告）日：1989-01-24

  3-Hydroxybenzo[b]thiophene-2-carboxamide derivatives have been prepared by: (1) treating a substituted 2-halobenzoate with a thioacetamide. (2) treating a substituted thiosalicylate with an appropriately substituted haloacetamide; and (3) further synthetic modification of compounds prepared above. These compounds have been found to be effective inhibitors of both cyclooxygenase and lipoxygenase and thereby useful in the treatment of pain, fever, inflammation, arthritic conditions, asthma, allergic disorders, skin diseases, cardiovascular disorders, psoriasis, inflammatory bowel disease, glaucoma or other prostaglandins and/or leukotriene mediated diseases.

  3-羟基苯并[b]噻吩-2-甲酰胺衍生物已通过以下方法制备：(1)用硫代乙酰胺处理取代的2-卤代苯甲酸酯。(2)用适当取代的卤代乙酰胺处理取代的硫代水杨酸酯；以及(3)对上述制备的化合物进行进一步的合成修饰。已发现这些化合物对环氧化酶和脂氧合酶均具有有效抑制作用，因此在治疗疼痛、发热、炎症、关节炎、哮喘、过敏性疾病、皮肤病、心血管疾病、银屑病、炎症性肠病、青光眼或其他前列腺素和/或白三烯介导的疾病治疗中具有用处。
• Carboline Derivatives Useful in the Inhibition of Angiogenesis
  申请人：MOON Young-Choon

  公开号：US20070281962A2

  公开（公告）日：2007-12-06

  In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of VEGF production, in the inhibition of angiogenesis, and/or in the treatment of cancer, diabetic retinopathy or exudative macular degeneration are provided. In another aspect of the invention, methods are provided for the inhibition of VEGF production, the inhibition of angiogenesis, and/or the treatment of cancer, diabetic retinopathy or exudative macular degeneration using the compounds of the invention.

  根据本发明，已经鉴定出了抑制VEGF转录后表达的化合物，并提供了它们的使用方法。在本发明的一个方面，提供了在抑制VEGF产生、抑制血管生成和/或治疗癌症、糖尿病视网膜病变或渗出性黄斑变性方面有用的化合物。在本发明的另一个方面，提供了使用本发明中的化合物抑制VEGF产生、抑制血管生成和/或治疗癌症、糖尿病视网膜病变或渗出性黄斑变性的方法。
• CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS
  申请人：Moon Young-Choon

  公开号：US20100179132A1

  公开（公告）日：2010-07-15

  In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of VEGF production, in the treatment of solid tumor cancer, and in reducing plasma and/or tumor VEGF levels, are provided. In another aspect of the invention, methods are provided for the inhibition of VEGF production, the treatment of cancer, and the reduction of plasma and/or tumor VEGF levels, using the compounds of the invention.

  根据本发明，已经鉴定出抑制VEGF在转录后表达的化合物，并提供了它们的使用方法。本发明的一方面提供了用于抑制VEGF生产、治疗实体肿瘤癌和减少血浆和/或肿瘤VEGF水平的化合物。本发明的另一方面提供了使用本发明中的化合物抑制VEGF生产、治疗癌症和减少血浆和/或肿瘤VEGF水平的方法。
• [EN] SMALL MOLECULE INHIBITORS OF GALECTIN-3<br/>[FR] INHIBITEURS À PETITES MOLÉCULES DE GALECTINE-3
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2019067702A9

  公开（公告）日：2019-04-25
• ADMINISTRATION OF CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES
  申请人：Cao Liangxian

  公开号：US20100158858A1

  公开（公告）日：2010-06-24

  In accordance with the present invention, compounds are provided which are useful in a method or in the manufacture of a medicament for post-transcriptionally inhibiting the expression of VEGF in a subject in need thereof comprising inhibiting VEGF mRNA translation by orally administering said medicament once, twice or thrice daily to the subject.